Literature DB >> 17262059

High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.

J El-Cheikh1, C Faucher, S Fürst, S Duran, P Berger, N Vey, A-M Stoppa, R Bouabdallah, J-A Gastaut, P Viens, D Blaise, M Mohty.   

Abstract

The use of high-dose corticosteroids for graft-versus-host disease (GVHD) treatment represents a major risk factor for long-term invasive fungal infections. The aim of this study was to investigate the safety and tolerance of weekly prophylactic administration of once-weekly high-dose (7.5 mg/kg) of liposomal amphotericin B (L-AmB) therapy in 21 adult patients receiving high-dose prednisone (2 mg/kg/day) for acute GVHD therapy after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT). Patients received a median of 4 (range, 1-8) infusions of L-AmB. Seven patients (33%; 95% confidence intervals (CI), 13-53%) discontinued taking the study drug owing to study drug-related adverse events, including elevated serum creatinine (>1.5 times from baseline values; n=5), hypotension and pain (n=1), and violent chest pain and arrhythmia (n=1). The overall frequency of infusion-related reactions was 29% (n=6; 95% CI, 10-48%), but these reactions were always transient and relieved by stopping the infusion. This safety data provide support for an efficacy study of this prophylaxis strategy, because this may help further improving the outcome of RIC or nonmyeloablative allo-SCT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262059     DOI: 10.1038/sj.bmt.1705592

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Authors:  Jean El Cheikh
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

3.  Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.

Authors:  Lizbeth Cahuayme-Zuniga; Russell E Lewis; Victor E Mulanovich; Dimitrios P Kontoyiannis
Journal:  Med Mycol       Date:  2011-11-22       Impact factor: 4.076

Review 4.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

5.  Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Authors:  Luciana Annino; Anna Chierichini; Barbara Anaclerico; Erica Finolezzi; Marianna Norata; Stefania Cortese; Maria Iris Cassetta; Stefania Fallani; Andrea Novelli; Corrado Girmenia
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

6.  Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation.

Authors:  Joshua Wolf; Monica A Slavin
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 7.  Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.

Authors:  S M Rubinstein; K A Culos; B Savani; G Satyanarayana
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

Review 8.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 9.  Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.

Authors:  Baldeep Wirk; John R Wingard
Journal:  Mycopathologia       Date:  2009-02-27       Impact factor: 2.574

10.  Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Cho-Hao Lee; Chin Lin; Ching-Liang Ho; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.